Eli Lilly and Company (LLY) Halts Experimental Study of Muscle-Sparing Obesity Drug

Eli Lilly and Company (NYSE:LLY) is among the 10 Best Money Making Stocks to Invest In. According to a U.S. registry of clinical trials, the firm has halted an experimental drug study designed to stop obesity patients from excessive muscle loss due to undisclosed strategic business reasons.

The company was testing Bimagrumab, alone or in combination with Tirzepatide, to see how the drugs worked in lowering the body weight of type 2 diabetes patients who were obese or overweight. Tirzepatide is the active ingredient found in Eli Lilly and Company (NYSE:LLY)’s obesity treatment, Zepbound.

The trial was closed on June 10, less than a month after it was initiated, said the latest update on the registry. However, a similar study in obese patients who are not diabetic remains active.

A company spokesperson was quoted as saying the following by Reuters on the development:

“We routinely evaluate our clinical development programs to optimize the potential for each product.”

Several drugmakers are currently pushing to develop such therapies, with most of them being tested in combination with Eli Lilly and Company (NYSE:LLY)’s Zepbound or Novo Nordisk’s Wegovy.

In 2023, Lilly acquired privately held Versanis for nearly $2 billion and gained access to the latter’s lead drug, bimagrumab, which acts on fat cells without prompting lean mass loss and reducing appetite.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Renaissance Technologies Portfolio: 10 Biggest Stocks and 12 Best Defense Stocks to Buy Right Now.

Disclosure: None.